10 Best Get Rich Quick Stocks To Invest In

5. Sagimet Biosciences Inc. (NASDAQ:SGMT)

Current Share Price as of February 19: $4.06

Stock Beta Rating: 2.30

Number of Hedge Fund Holders: 16

Sagimet Biosciences Inc. (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company. It develops therapeutics called fatty acid synthase (FASN) inhibitors for treating diseases resulting from dysfunctional metabolic pathways. The company continues to elicit strong interest owing to the tremendous potential of its lead candidate drug, denifanstat, for the treatment of nonalcoholic steatohepatitis (NASH).

Denifanstat has shown promise as a revolutionary treatment for NASH, particularly in patients with more severe F3 fibrosis. The medication has consistently shown improvement in fibrosis and NASH symptoms. It’s also being tailored as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), which is predicted to have a $15 billion market potential.

The U.S. Food and Drug Administration (FDA) awarded the medication Breakthrough Therapy Designation, further confirming its potential. This designation is anticipated to speed up the development and review process, which could hasten the treatment’s release onto the market. The business had $188 million in cash reserves at the end of the third quarter of 2024. According to management, this cash position will give them enough leeway in 2025.